[Bacterial vaginosis and preterm delivery risk].
The aim of the study was to evaluate the impact of early, second trimester bacterial vaginosis [BV] on the number of threatened preterm deliveries. Group A consisted of 52 pregnant women in whom BV was diagnosed in the beginning of the 2nd trimester of pregnancy. Group A patients were treated with a 10 day course of metronidazole 0.5 g vaginally daily. Group B consisted of 122 pregnant women without BV. The number of cases with threatened preterm delivery was prospectively assessed in both groups. There were 28 cases of threatened preterm delivery in group A (53.8%) and 6 similar cases in group B (4.9%) (p < 0.05--Chi square test d.f.1). All cases (n = 20) of BV at the time of hospitalization due to threatened preterm delivery occurred in group A. The cases of threatened preterm delivery occurred significantly more frequently in pregnant patients who had the BV diagnosed in the beginning of the 2nd trimester. This may suggest the link between BV and the occurrence of threatened preterm deliveries.
Milewicz
Tomasz
T
Klinika Endokrynologii Ginekologicznej, Collegium Medicum, Uniwersytetu Jagiellońskiego w Krakowie. endomil@interia.pl
Hejnar
Janusz
J
Jach
Robert
R
Jaworowski
Andrzej P
AP
Piskorz
Tomasz
T
Gach
Andrzej
A
Krzysiek
Józef
J
D000282:Administration, Intravaginal; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D015984:Causality; D016009:Chi-Square Distribution; D015897:Comorbidity; D005260:Female; D006801:Humans; D008795:Metronidazole / Q000627:therapeutic use; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy / Q000453:epidemiology*; D011262:Pregnancy Trimester, Second; D047928:Premature Birth / Q000453:epidemiology*; D012307:Risk Factors; D016585:Vaginosis, Bacterial / Q000188:drug therapy / Q000453:epidemiology*
D000900:Anti-Bacterial Agents; D008795:Metronidazole